Low Crosslinking Cation Exchange Polymers for Hyperkalemia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hyperkalemia, such as potassium-binding resins like Kayexalate, are poorly tolerated due to gastrointestinal side effects and dosing complexities, leading to low patient compliance and suboptimal management of chronic hyperkalemia.
Innovation Solution
Development of crosslinked cation exchange polymers with low levels of crosslinking and improved particle size distribution, providing a more palatable and tolerable option for potassium binding, allowing for effective potassium excretion and improved patient compliance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If crosslinked cation exchange polymers with high levels of crosslinking are used for potassium binding, then binding capacity is improved, but patient tolerance deteriorates due to gastrointestinal side effects
Solution Approach 1:
The patent applies parameter changes by reducing the crosslinking level from conventional high levels (typically 8-16% divinylbenzene) to low levels (0.1-5% divinylbenzene). This parameter modification transforms the polymer's properties to achieve both adequate binding capacity and improved patient tolerance by reducing gastrointestinal side effects such as constipation and nausea.
Solution Approach 2:
The patent employs composite materials by creating crosslinked cation exchange polymers with specific compositions that combine low crosslinking levels with controlled particle size distributions. The composite structure incorporates functional groups for potassium binding while maintaining a matrix that minimizes gastrointestinal irritation, achieving a balance between efficacy and tolerability.
2Productivity
If conventional potassium-binding resins are administered, then potassium excretion is achieved, but patient compliance deteriorates due to dosing complexities and poor tolerability
Solution Approach 1:
The patent modifies operational parameters by optimizing particle size distribution within specific ranges (0.5-2.0 mm for oral administration). This parameter optimization improves ease of administration and patient compliance while maintaining effective potassium excretion, as the controlled particle size enhances dissolution and reduces gastrointestinal discomfort.
Solution Approach 2:
The patent applies local quality by creating polymers with non-uniform crosslinking density and controlled particle size distributions. Different regions of the polymer matrix have optimized properties for either binding capacity or gastrointestinal tolerability, allowing the material to simultaneously achieve effective potassium excretion and improved patient compliance.
3Stability of the object's composition
If high crosslinking levels are used in cation exchange polymers, then structural stability is improved, but particle size control and uniformity deteriorate
Solution Approach 1:
The patent applies parameter changes by inverting the traditional approach: instead of using high crosslinking to achieve stability, it uses low crosslinking levels (0.1-5% divinylbenzene) combined with controlled particle size distribution (0.5-2.0 mm). This parameter inversion achieves both structural stability and manufacturing precision, as the lower crosslinking allows for better control over particle formation and size uniformity during synthesis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crosslinked cation exchange polymers achieve higher potassium excretion and improved patient tolerance, enabling effective chronic management of hyperkalemia with reduced dosing frequency and improved mouth feel, thus enhancing treatment efficacy.
Implementation Method 1
crosslinked cation exchange polymers with a low level of crosslinking for improved potassium excretion
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention is directed to compositions and methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of cation exchange polymers with low crosslinking for improved potassium excretion and for beneficial physical properties to increase patient compliance. In particular the application discloses the use of crosslinked calcium polystyrene sulfonate with a crosslinking of less than 5%.